Highlights ObsEva SA

Equities

OBSEF

CH1260041939

Delayed OTC Markets Other stock markets 02:33:29 2024-07-09 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		+9,900.00%	-99.71%

2023	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
2023	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	23-04-20	MT
ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
ObsEva says Swiss Court Dismisses Moratorium Proceedings as Company No Longer Over-indebted	22-12-19	MT
ObsEva Says Swiss Court Granted Request to End Moratorium Proceedings; Shares Gain Pre-Bell	22-12-19	MT
ObsEva Regains Compliance With Nasdaq Listing Requirement of Minimum Stockholders' Equity	22-12-14	MT
ObsEva Sinks To Q3 Loss As Operating Income Other Than Revenue Slumps	22-12-01	MT
ObsEva Swings to Loss in Q3 -- Shares Drop Late Hours	22-12-01	MT
ObsEva SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-01	CI
Exchange-Traded Funds Preview: Encouraging Data Expectations Lifting ETFs, Equities Futures	22-11-22	MT
ObsEva Sells Rights to Experimental Preterm Labor Drug to Xoma for Up to $113 Million; Shares Surge Pre-Bell	22-11-22	MT
ObsEva to Sell Rights to Preterm Labor Treatment for Up to $113 Million	22-11-22	MT
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million	22-11-22	CI
XOMA Corporation acquired Rights to Ebopiprant from ObsEva SA for $113 million.	22-11-21	CI
ObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug	22-10-13	MT
ObsEva SA Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China	22-10-13	CI
ObsEva Receives Nasdaq Notice for Non-Compliance With Stockholders' Equity Rule	22-08-22	MT
ObsEva Gets Non-compliance Notice From Nasdaq Over Minimum Equity	22-08-22	MT
ObsEva SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
ObsEva to Restructure After FDA Cites Issues With Uterine Fibroids Drug Application; Shares Plunge	22-07-27	MT
ObsEva Wins UK Approval For Uterine Fibroids Treatment	22-06-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ObsEva SA

Equities

OBSEF

CH1260041939

Highlights

Filters